The UK and US have concluded a key bilateral deal that will maintain no levies on UK drug shipments going into the US market.
Key Provisions of the Accord
Under the terms of the agreement, the UK has agreed to increase spending on medicines through the NHS. This commitment secures that tariffs on these key goods will be held at zero for a duration of the next three years.
This development is in response to earlier statements to significantly raise duties on patented drug imports, with increases floated reaching one hundred percent.
"This deal between the United Kingdom reinforces the global environment for innovative medicines and introduces much-needed balance to transatlantic medicine commerce," a statement said.
Economic Impact
Pharmaceuticals represent one of the Britain's biggest exports to the US, which is by far the largest market for large UK drugmakers.
Statistics reveal that in the one-year period leading up to the third quarter, the UK sold drugs valued at £11.1bn to the US. This value represented a significant portion of all goods exports in that timeframe.
"This guarantee protects jobs, boosts investment and facilitates the UK to emerge as a international leader for medical research," a government official stated.
Detailed NHS Changes
The pact includes several specific commitments from the UK:
- Higher Cost Ceiling: The UK will lift the affordability limit at which it deems new therapies to be too expensive by 25%.
- Increased NHS Spending: There is a aim to raise overall public funding on treatments from 0.3% of the national economy to 0.6% over the coming ten years.
- Refund Ceiling: The sum manufacturers must return to the NHS to stay within budget will be capped at fifteen percent. Last year, refunds topped twenty percent.
Broader Context
This agreement follows a ongoing row between the pharmaceutical industry and the UK government over drug pricing and regulatory access.
These tensions were heightened by claims that American consumers were paying several times more for the identical medicines than patients in the Britain and the EU.
Over the last 18 months, several major manufacturing plans in the UK have been paused or scrapped, while major expansions have been announced toward projects in the United States.
A senior figure stated that the NHS needed to spend more on medicines, noting that its budget allocation on drugs had shrunk as a percentage of its resources over the past decade.
